Outpatient treatment of COVID-19 and incidence of
post-COVID-19 condition over 10 months (COVID-OUT):
a multicentre, randomised, quadruple-blind, parallel-group,
phase 3 trial
Post-COVID-19 condition (also known as long COVID) is an emerging chronic illness potentially affecting millions of people. We aimed to evaluate whether outpatient COVID-19 treatment with metformin, ivermectin, or fluvoxamine soon after SARS-CoV-2 infection could reduce the risk of long COVID.
Outpatient treatment with metformin reduced long COVID incidence by about 41%, with an absolute reduction of 4·1%, compared with placebo. Metformin has clinical benefits when used as outpatient treatment for COVID-19 and is globally available, low-cost, and safe.
A literature hub for tracking up-to-date scientific information about the 2019 novel Coronavirus.
LitCovid is a curated literature hub for tracking up-to-date scientific information about the 2019 novel Coronavirus. It is the most comprehensive resource on the subject, providing central access to 29074 (and growing) relevant articles in PubMed. The articles are updated daily and are further categorized by different research topics and geographic locations for improved access.
Resources to help schools keep students and staff safe
The COVID Safety for Schools Course is a high-quality video-based course for Australian schools. It explains the realities of COVID in clear, easy-to-understand language and provides practical advice on how to minimise the risk of COVID spreading at schools, based on the latest science.
SARS-CoV-2 infection and persistence in the human body and brain at autopsy
Coronavirus disease 2019 (COVID-19) is known to cause multi-organ dysfunction1,2,3 during acute infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), with some patients experiencing prolonged symptoms, termed post-acute sequelae of SARS-CoV-2. However, the burden of infection outside the respiratory tract and time to viral clearance are not well characterized, particularly in the brain. Here we carried out complete autopsies on 44 patients who died with COVID-19, with extensive sampling of the central nervous system in 11 of these patients, to map and quantify the distribution, replication and cell-type specificity of SARS-CoV-2 across the human body,
Download a printable PDF of this zine here! Print on 4 sheets of paper, double-sided, short-edge binding. Fold it in half, then staple in the middle. Regular PDF here.
Join the Canadian Covid Society in our mission to save lives
Our Mission
At the Canadian Covid Society, we strive to protect the health and safety of people in Canada against the harms of COVID-19 and long Covid, through education, engaging and empowering the public and organizations with scientific knowledge.
What COVID-19 Does To The Body (Fourth Edition, March 2024)
Over 130+ Studies On COVID-19 Effects & Prevention
Since our last edition in December, the CDC has now empowered employers to force workers sick & contagious with COVID-19 to work through an active viral infection, spreading pestilence to others. Along with an uptick in LongCOVID as a result of this past year’s pandemic mismanagement, we also have a growing body of research showing the many harms that even “mild” (not hospitalized) COVID-19 infections can leave on the human body. This round, the largest number of developments have come from understanding COVID-19’s effects on children, the brain, the immune system, and Long COVID – a disability afflicting millions of Americans, including kids.